

# Brilliant Violet 750™ anti-human HLA-DR

**Catalog # /** 2138360 / 100 tests  
**Size:** 2138355 / 25 tests

**Clone:** L243

**Isotype:** Mouse IgG2a,  $\kappa$

**Immunogen:** Human rheumatoid synovial fluid cells and fibronectin-purified monocytes.


**Reactivity:** Human, Non-human primate, Other

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 750™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 750™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Workshop Number:** VI MA36

**Concentration:** Lot-specific



Human peripheral blood lymphocytes were stained with CD19 FITC and HLA-DR (Clone L243) Brilliant Violet 750™ (left) or CD19 FITC only (right).

## Applications:

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5  $\mu$ l per million cells in 100  $\mu$ l staining volume or 5  $\mu$ l per 100  $\mu$ l of whole blood.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** The L243 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. Clone L243 binds a conformational epitope on HLA-DR $\alpha$  which depends on the correct folding of the  $\alpha\beta$  heterodimer.<sup>19</sup>

Additional reported applications (for the relevant formats) include: immunoprecipitation<sup>8</sup>, Western blotting<sup>8</sup>, *in vitro* blocking of mixed lymphocyte reactions<sup>9,10</sup>, depletion of MHC class II cells<sup>7</sup>, and immunohistochemical staining of acetone-fixed frozen sections<sup>4,5</sup>.

**Application  
References:**

1. Brodsky F. 1984. *Immunogenetics* 19:179.
2. Robbins P, et al. 1987. *Human Immunol.* 18:301.
3. Stites D, et al. 1986. *Clin. Immunol. Immunopathol.* 38:161.
4. Warnke R, et al. 1980. *J. Histochem. Cytochem.* 28:771. (IHC)
5. Engleman E, et al. 1981. *P. Natl. Acad. Sci. USA* 78:1791. (IHC)
6. Zipf T, et al. 1981. *Cancer Res.* 41:4786.
7. Goodier M, et al. 2000. *J. Immunol.* 165:139. (Depletion)
8. Esser M, et al. 2001. *J. Virol.* 75:6173. (IP, WB)
9. Kalka-Moll WM, et al. 2002. *J. Immunol.* 169:6149. (Block)
10. Wang RF, et al. 1999. *Science* 284:1351. (Block)
11. Zaba LC, et al. 2007. *J. Exp. Med.* 204:3183. [PubMed](#)
12. Fujita H, et al. 2009. *P. Natl. Acad. Sci. USA* 106:21795. [PubMed](#)
13. Charles N, et al. 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
14. Goncalves RM, et al. 2010. *Infect. Immun.* 78:4763. [PubMed](#)
15. Yoshino N, et al. 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
16. Kim WK, et al. 2006. *Am. J. Pathol.* 168:822. (FC)
17. Stein R, et al. 2011. *Leuk. Lymphoma* 52:273.
18. Galkowska H, et al. 1996. *Vet. Immunol. Immunopathol.* 53:329.
19. Moro M, et al. 2005. *BMC Immunol.* 6:24.
20. Lauterbach N, et al. 2014. *Mol Immunol.* 59:19. [PubMed](#)

---

**Description:** HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD  $\alpha$  (heavy) chain and a 27 kD  $\beta$  (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4<sup>+</sup> T cells.

**Antigen  
References:**

1. Levacher M, et al. 1990. *Clin. Exp. Immunol.* 81:177.
2. Terstappen L, et al. 1990. *J. Leukocyte Biol.* 48:138.
3. Edwards JA, et al. 1986. *J. Immunol.* 137:490.
4. van Es A, et al. 1984. *Transplantation* 37:65.
5. O'Doherty U, et al. 1994. *Immunology* 82:487.
6. Thomas R, et al. 1994. *J. Immunol.* 153:4016.
7. Grouard G, et al. 1996. *Nature* 384:364.